Premium
Thrombomodulin Attenuates Inflammatory Damage Due to Liver Ischemia and Reperfusion Injury in Mice in Toll‐Like Receptor 4–Dependent Manner
Author(s) -
Kadono K.,
Uchida Y.,
Hirao H.,
Miyauchi T.,
Watanabe T.,
Iida T.,
Ueda S.,
Kanazawa A.,
Mori A.,
Okajima H.,
Terajima H.,
Uemoto S.
Publication year - 2017
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.13991
Subject(s) - thrombomodulin , medicine , proinflammatory cytokine , inflammation , pharmacology , reperfusion injury , liver injury , liver transplantation , transplantation , in vivo , tlr4 , hmgb1 , immunology , ischemia , thrombin , biology , platelet , microbiology and biotechnology
Liver ischemia reperfusion injury ( IRI ) is an important problem in liver transplantation. Thrombomodulin ( TM ), an effective drug for disseminated intravascular coagulation, is also known to exhibit an anti‐inflammatory effect through binding to the high‐mobility group box 1 protein ( HMGB ‐1) known as a proinflammatory mediator. We examined the effect of recombinant human TM ( rTM ) on a partial warm hepatic IRI model in wild‐type (WT) and toll‐like receptor 4 ( TLR ‐4) KO mice focusing on the HMGB ‐1/ TLR ‐4 axis. As in vitro experiments, peritoneal macrophages were stimulated with recombinant HMGB ‐1 protein. The rTM showed a protective effect on liver IRI . The rTM diminished the downstream signals of TLR ‐4 and also HMGB ‐1 expression in liver cells, as well as release of HMGB‐1 from the liver. Interestingly, neither rTM treatment in vivo nor HMGB ‐1 treatment in vitro showed any effect on TLR ‐4 KO mice. Parallel in vitro studies have confirmed that rTM interfered with the interaction between HMGB ‐1 and TLR ‐4. Furthermore, the recombinant N‐terminal lectin‐like domain 1 (D1) subunit of TM ( rTMD 1) also ameliorated liver IRI to the same extent as whole rTM . Not only rTM but also rTMD 1 might be a novel and useful medicine for liver transplantation. This is the first report clarifying that rTM ameliorates inflammation such as IRI in a TLR ‐4 pathway–dependent manner.